CONFERENCE PRESENTATION · September 12, 2022
SCDM 2022 Annual Conference Keynote Session - Landscape shifts in clinical research and clinical evidence generation
Overview
The pandemic played a key role in the evaluation across the drug lifecycle, especially when we talk about data. But a central challenge has been data and how to handle data quality mismatch, and we saw a big need for measuring and documenting data quality across data sets.
Clinical studies are shifting to adapt to demands and are covering longitudinal data and evidence. At the same time, regulators and industries are addressing data quality issues. It is now clear that clinical studies in the future will look different, but how? And how will the role of CDM change after incorporating data sources into clinical studies? What skills will be needed?
Meet the Presenter
Amy Abernethy
President, Clinical Studies Platform
Verily Life Sciences
Amy Abernethy is the President of Verily’s Clinical Studies Platforms, where she oversees the company’s clinical evidence generation platform product vision and related clinical research portfolio. Dr. Abernethy was most recently Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency’s acting Chief Information Officer.
Verily Life Sciences
Dr. Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications.
Need support?
Technical support:
Click on the help button on the bottom right, select contact support and email the BlueSky team with any technical issues. Otherwise e-mail directly to support@blueskyelearn.com or call +1-888-705-6002 for immediate help.
General support:
The SCDM Learning team is here to help. Contact us at learning@scdm.org or call +32 232 024 87.